ANS-6637 is a Phase-2 ready first-in-class compound that utilizes a published novel pathway for the treatment of addiction.
ANS-6637 is highly selective ALDH2 Inhibitor that modifies dopaminergic tone by preventing pathophysiologic dopamine surges and associated craving without changes to basal dopamine. This profile, which prevents craving and drug seeking behavior, has the potential to be used as pharmacotherapy for substance and behavior and based addictions.
MOA published in Nature Medicine
ALDH2 inhibition prevents pathophysiologic dopamine surges and associated craving without changes to basal dopamine
Dopamine surge is part of the reward circuity and common to all substance and behavioral addiction.
Addiction hijacks the reward circuit to create pathophysiologic surges.
ALDH2 Inhibition: Published Pre-Clinical Efficacy Data
In multiple pre-clinical models of substance abuse and anxiety, ALDH2 inhibition prevents dopamine surge without changes to basal dopamine levels, and
ALDH2 Inhibition: Published Neurobiologic Model of Addiction and Mechanism of Action